SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
PHOENIX, Jan. 25, 2016 -- Insys Therapeutics, Inc. (Nasdaq:INSY) (“Insys” or “the Company”) today issued the following statement in response to misleading reports in the media regarding the practices of its Patient Services Center:
"Insys is committed to working with health care providers, insurance companies, payors, pharmacies, and most importantly, patients, to help ensure that patients have access to the Company’s breakthrough cancer pain drug, Subsys®, a product that has helped and continues to help many patients suffering from excruciating pain related to certain cancers and cancer treatments.
"As for many specialty drugs, the path patients must travel to obtain third-party payor access and reimbursement can be complex and difficult to navigate. Insys’ Patient Services Center is a group of dedicated employees who are committed to helping patients navigate this complex environment in order to access the medications that their practicing health care provider has deemed appropriate or necessary for their treatment. These support services initiate with patient consent at the time a prescription is written, and may continue according to the patient’s needs.
"Insys requires its Patient Services Center personnel undergo specific training on applicable laws and regulations and continues to strive to comply with applicable laws and regulations through its compliance policies and procedures.
"Insys rejects the recent media reports’ account of the Company’s practices as misleading and unreliable, especially in light of the biased agenda held by the individuals who made these misrepresentations."
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets one product, Subsys® (fentanyl sublingual spray). The Company recently submitted a New Drug Application to the U.S. Food and Drug Administration for Syndros® (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.
Subsys® and Syndros® are registered trademarks of Insys Therapeutics, Inc.
Investor Contact: Lisa M. Wilson, President In-Site Communications, Inc. Phone: 212-452-2793 Email: [email protected]
